DCGO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
DCGO is not a good buy right now for a Beginner, long-term investor with $50,000-$100,000 to deploy. The stock is trading below key resistance and in a weak technical position, while fundamentals are still not showing profitability. Although revenue growth and guidance improvement are positives, the lack of a clear buy signal, continued EBITDA losses, and bearish analyst tone make this a hold rather than an immediate buy.
The current trend is bearish. MACD histogram is negative at -0.0109 and still contracting, RSI_6 is 35.357, which is weak but not yet oversold, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Price at 0.5811 is below pivot 0.624 and near support at S1 0.559, showing the stock is still under pressure. The short-term pattern data suggests some upside potential, but the broader trend remains weak.
["Q1 2026 revenue was $75.6 million, showing continued operating activity.", "2026 revenue guidance was raised to $300 million-$315 million.", "SteadyMD generated over $9 million in Q1 revenue with 38% year-over-year growth in visits and lab orders.", "Analyst Stifel still maintains a Buy rating and sees value in the transportation segment.", "Potential strategic alternatives could create shareholder value if executed well."]
["Q1 2026 adjusted EBITDA was a loss of $10.2 million, showing the company is still unprofitable.", "Cash and cash equivalents fell to $59.9 million from $68.3 million at year-end 2025, implying short-term cash pressure.", "Canaccord lowered its price target to $1 from $1.50 and kept only a Hold rating.", "The stock has no AI Stock Picker or SwingMax signal today.", "Hedge funds and insiders show no significant buying trends.", "Technical trend remains bearish with price below major moving averages."]
In the latest reported quarter, Q1 2026, DocGo posted revenue of $75.6 million, which supports a growth narrative, and management raised full-year 2026 revenue guidance to $300 million-$315 million. However, profitability remains weak with an adjusted EBITDA loss of $10.2 million. The latest quarter season is Q1 2026. SteadyMD also contributed growth, generating over $9 million in revenue and expanding visit/lab-order volume by 38% year over year. Overall, revenue growth is improving, but earnings quality and cash burn are still concerns.
Analyst sentiment is mixed but leaning cautious. On 2026-03-25, Canaccord cut its price target to $1 from $1.50 and kept a Hold rating, citing mixed Q4 results and ongoing work needed to scale the Mobile Health business and restore profitability. On 2026-03-17, Stifel cut its target to $2.50 from $4 but kept a Buy rating, pointing to improved transport growth and possible asset value above the current share price. Wall Street pros are split: the bullish case is based on asset value and transportation upside, while the bearish case focuses on weak profitability and execution risk.
